Clinical Trial Update: Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib in relapsed or refractory non-small cell lung cancer among non-smokers or former light smokers; trial terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-06-04